--Claim 128. A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a variable light (VL) domain having an amino acid sequence of SEQ ID NO: 11, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

Claim 129. A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a variable heavy (VH) domain having an amino acid sequence of SEQ ID NO: 48, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

Claim 130. The antibody of claim 128 further comprising a VH domain having an amino acid sequence of SEQ ID NO: 48.

Claim 131. A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH complementarity determining region (CDR) 1 having an amino acid sequence of SEQ ID NO: 10, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

Claim 132. A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH CDR2 having an amino acid sequence of SEQ ID NO: 19, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

Claim 133. A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH CDR3 having an amino acid sequence of SEQ ID NO: 20, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

Claim 134. A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 39, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.--

137. (New) The method of claim 131, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

138. (New) The method of claim 131, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

139. (New) The method of claim 131, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

140. (New) The method of claim 132, wherein the antibody further comprises a VL CDR 1 having an amino acid sequence of SEQ ID NO:39.

141. (New) The method of claim 132, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

142. (New) The method of claim 132, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

143. (New) The method of claim 133, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

144. (New) The method of claim 133, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

145. (New) The method of claim 133, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

17 4
146. (New) The method of claim 131, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

18 4
147. (New) The method of claim 131, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

19 5
148. (New) The method of claim 132, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

20 17
149. (New) The method of claim 146, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

21 17
150. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

22 17
151. (New) The method of claim 146, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

23 17
152. (New) The method of claim 146, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

24 18
153. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

25 18
154. (New) The method of claim 147, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

26 18
155. (New) The method of claim 147, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

27 19
156. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

28 19
157. (New) The method of claim 148, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

29 19
158. (New) The method of claim 148, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

30 20
159. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

31 20
160. (New) The method of claim 149, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

32 20
161. (New) The method of claim 149, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

33 7
162. (New) The method of claim 134, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

34 7
--Claim 163. The method of claim 134, wherein the antibody further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.--

35 33
165. (New) The method of claim 162, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

36 33
166. (New) The method of claim 162, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

37 33
167. (New) The method of claim 162, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

38 33
168. (New) The method of claim 162, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

39 34
169. (New) The method of claim 163, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

40 34
170. (New) The method of claim 163, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

41 34
171. (New) The method of claim 163, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

--Claim 172. A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO: 5, a VLCDR3 having an amino acid sequence of SEQ ID NO: 6, and a VH CDR1 having an amino acid sequence of SEQ ID NO: 10, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

Claim 173. A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO: 5, a VLCDR3 having an amino acid sequence of SEQ ID NO: 6, and a VH CDR2 having an amino acid sequence of SEQ ID NO: 19, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

Claim 174. A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO: 5, a VLCDR3 having an amino acid sequence of SEQ ID NO: 6, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 20, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.--

45 35
175. (New) The method of claim 165, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

46 35
176. (New) The method of claim 165, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

47 35
177. (New) The method of claim 165, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

48 17
178. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

49 17
179. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

50 17
180. (New) The method of claim 146, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

51 17
181. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

52 18
182. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

53 18
183. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

54 18
184. (New) The method of claim 147, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

55 18

185. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

56 19

186. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

57 19

187. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

58 19

188. (New) The method of claim 148, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

59 19

189. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

60 20

190. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid scquence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

61 20

191. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

62 20

192. (New) The method of claim 149, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

63 20

193. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

64 1 2 3 4-7

194. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the effective amount is 15 mg/kg or less, 10 mg/kg or less, 5 mg/kg or less or 3 mg/kg or less or 1.5 mg/kg or less.

65 1 2 3 4-7

195. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the effective neutralizing titer is at least 1 μg/ml, at least 2 μg/ml , at least 4 μg/ml, at least 6 μg/ml, at least 30 μg/ml, 35 μg/ml, at least 40 μg/ml, at least 50 μg/ml, at least 75 μg/ml, at least 100 μg/ml, at least 150 μg/ml or at least 200 μg/ml.

66 1 2 3 4-7

196. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the effective neutralizing titer is maintained for at least 20 days, at least 25 days or at least 30 days after administration of the dose.

67 1 2 3 4-7

197. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the antibody is administered by a nebulizer or inhaler.

68 1 2 3 4-7

198. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the antibody is administered intramusclarly, intravenously or subcutaneously.

69 1 2 3 4-7

199. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the antibody is a monoclonal antibody, a human antibody, a humanized antibody, a multispecific antibody, a chimeric antibody, a Fab fragment, a single-chain Fv or a single chain antibody.

70 1 2 3 4-7

200. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the antibody is administered 1, 2, 3, 4 or 5 times during the RSV season.

71 1 2 3 4-7

201. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the mammal is a human subject.

72 71

202. (New) The method of claim 201, wherein the human subject is a human infant, a human infant born prematurely or at risk of hospitalization for a RSV infection, a human subject which has had a bone marrow transplant, an elderly human subject, or a human subject which has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

73 1 2 3 4-7

203. (New) The method of any one of claims 128, 129, 130 or 131-134 further comprising administering to the mammal hormonal therapy, immunotherapy or an anti-inflammatory agent.